Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 3.53% is 93% below its 4-year average of 50.17%, near the low end of its 4-year range (1.89%–1728.20%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.80% above its 12-month average of 2.92%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.53%.
DEBT TO ASSETS RATIO
3.53%
DEBT TO ASSETS RATIO AVG TTM
2.92%
DEBT TO ASSETS RATIO AVG 3Y
2.65%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+20.80%
CURRENT VS 3Y AVG
+33.09%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+3822.22%
vs the sector median at left
60 Degrees Pharmaceuticals, Inc.
Market Cap
$3.87M
Debt to Assets Ratio
3.53%
TTM Avg
2.92%
3Y Avg
2.65%
5Y Avg
N/A
Market Cap
$3.96M
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.77M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.69M
Debt to Assets Ratio
0.14%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.67M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.11M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | $3.87M | 3.53% | 2.92% | 2.65% | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.96M | 0.29% | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.79M | 0.16% | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.77M | 0.06% | N/A | N/A | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.69M | 0.14% | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.67M | 0.00% | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.11M | 0.00% | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.13M | 0.00% | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.58M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.53M | 0.00% | N/A | N/A | N/A |
Debt/Assets
3.5%
Debt/Equity
0.06
Current Ratio
2.32
Interest Coverage
-994.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 3.53% |
| 2026-03-31 | 2.25% |
| 2025-12-31 | 2.85% |
| 2025-09-30 | 2.30% |
| 2025-06-30 | 3.69% |
| 2025-03-31 | 2.60% |
| 2024-12-31 | 2.71% |
| 2024-09-30 | 2.11% |
| 2024-06-30 | 3.64% |
| 2024-03-31 | 1.89% |
| 2023-12-31 | 2.22% |
| 2023-09-30 | 2.06% |
| 2023-06-30 | 354.22% |
| 2023-03-31 | 316.27% |
| 2022-12-31 | 1728.20% |
| 2022-09-30 | 1268.82% |
| 2021-12-31 | 1349.42% |
